Ask a question

Autologous dermal fibroblasts for the correction of age-related skin changes (SPRS-therapy®). Results of 2-year clinical trials and post-marketing clinical studies

One of the innovative methods to correct the age-related skin changes is the use of cultured fibroblasts derived from the patient’s own skin. The technology called SPRS-therapy® (Service for Personal Regeneration of Skin) has been officially approved in 2011 in Russia (developed by the public biotech company Human Stem Cells Institute (HSCI), Moscow).

The results of two-year clinical trials with the application of SPRS-therapy to correct the age-related skin defects demonstrated, that after the intradermal transplantation (injections), cultivated autoDF (autologous dermal fibroblasts) fully integrated into the dermis and their biosynthetic activity maintained at least for 12 months. As a result, the increase of collagen content and skin hydration was observed as well as the increased thickness of the dermis. The abovementioned changes resulted in the increase of skin tension, elasticity, and thickness and in the decrease of an amount of wrinkles and their depth.

The results of post-marketing studies conducted by HSCI after the first year of the application of technology in clinics confirmed the safety and clinical efficacy of SPRS-therapy for correction of skin aging changes.

On the aesthetic medicine market, SPRS-therapy was introduced by HSCI in January 2011. Today the SPRS-therapy service is primarily offered through the leading dermatology and cosmetics clinics of Moscow and cities across Russia and CIS (>40). Currently, the total number of patients that received the procedure is more than 750, with more than 60% of those that have returned for the second and/or additional skin treatments (included in other areas besides the face).

SPRS-therapy complex, developed for correction of patient’s skin changes and aging prophylaxis, includes also SPRS-diagnostics service (the evaluation of morpho-functional properties of patient’s skin fibroblasts called Skin Passport®), which allows to build an individual SPRS-therapy program as well to provide recommendations on other instrumental and cosmetological procedures for the patient. An individual cryogenic bank of skin fibroblasts is created for each patient allowing to repeat the procedure on a regular basis without additional skin sampling.

CELLR4
CELLR4 2016; 4 (3): e2084